Results from Axial Therapeutics Phase1b/2a Study of AB-2004 in Adolescents with Autism Spectrum Disorder Met Primary Endpoint and Reduced Irritability and Other Symptoms Business Wire: December 3, 2020 Read More
Go back to Press Page
